Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€15.74

€15.74

-8.490%
-1.46
-8.490%
€21.22
 
06.02.26 / Frankfurt WKN: A2AFXS / Symbol: CRVS / Name: Corvus / Stock / Biotechnology & Medical Research / Small Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Financial data and news for Corvus

sharewise wants to provide you with the best news and tools for Corvus, so we directly link to the best financial data sources.

News

Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026

Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might

Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data: https://cdn.content.foolcdn.com/images/1umn9qeh/production/dbf4812d84ab78c74b512c7cb2e4d70bee11215c-1401x1251.png?w=1401&h=1251
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data

Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic